Who's saving the world? And who's endangering the world?

Under the outbreak, some of my friends around me are facing the phenomenon of being laid off, looking for new jobs. Vaccines really don't have the same impact on the status quo as getting a new job!

The global virus is now looking forward to the new crown vaccine. Recently, China, britain, Russia, the United States and other countries to develop a new crown vaccine has made some progress. But these candidates need further clinical trials to verify that global vaccine development remains "a revolution that has not yet been successful and still has to be worked on."

At present, hundreds of research teams around the world are accelerating the development of new crown vaccines along different technical routes, and effective vaccine candidates are expected by the end of the year. However, how long the antibody levels caused by the vaccine can be maintained, how the virus responds if the mutation is mutated, and whether the vaccine's capacity is up to the question. Therefore, the future of vaccine research and development needs to be viewed rationally.

Vaccine research is complex, and many vaccines that were well developed in the early stages have not been successfully introduced. Previous outbreaks of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) caused by the coronavirus have not yet been approved for sale. As research progresses, some of the current candidate vaccines may be abandoned due to a variety of problems.

Michael Ryan, executive director of THE WHO Emergency Project, said that while preliminary trial data on some candidate vaccines are promising, it is not possible to predict which vaccine will be fully clinically effective. Daniel Altman, professor of immunology at Imperial College London, said: "The key is the details, finding a vaccine is not that easy... Many problems can go wrong in the process. I'm not going to make a conclusion now. "

WHO Director-General Tan Desai agreed that there should be cautious optimism about the future of research and development of the new crown vaccine.

1

The Chinese research team said in a paper published in the British medical journal The Lancet on Tuesday that they have conducted a phase 2 clinical trial of a new coronavirus vaccine that has shown that it is safe and can induce an immune response. The trial assessed a new coronavirus vaccine for adenovirus vector recombinant. The team is currently conducting Phase 3 clinical trials.

The Team at the University of Oxford in the United Kingdom also published a paper in The Lancet on the same day, said they conducted a new coronavirus vaccine clinical trial has achieved preliminary results, the vaccine can induce the body's immune system to develop a stronger immune response, and does not cause serious side effects. The team is currently conducting larger vaccine clinical trials in the UK, Brazil and South Africa.

A new crown vaccine developed in Russia launched phase 1 clinical trial in June. One group of subjects were discharged from the hospital on July 20, and they all felt good. If Phase 2 and Phase 3 clinical trials go well, the first batch of new Russian-made vaccines is expected to go into production this fall, said Ginzburg, director of the National Center for Epidemiology and Microbiology in Gamalea.

A study published July 14 in the New England Journal of Medicine showed that the new coronavirus mRNA-1273, which has been conducted in clinical trials in the United States, stimulates the body's immune response to the new coronavirus and no serious adverse reactions have been reported. Developed by the U.S. National Institute of Allergy and Infectious Diseases in collaboration with Modner, the vaccine is a messenger rnaylate (mRNA) vaccine that works against the virus's stingy proteins. Modena will launch phase 3 of a randomized double-blind control clinical trial on July 27.

In the face of the new global virus, vaccine development needs to overcome difficulties and challenges are difficult and complex. Compared with the usual vaccine development, the development of the new crown vaccine can be said to be in the "fast track", because countries have put in place measures to speed up research and development. But vaccine development is not a race, and international cooperation is crucial to a final victory.

In the face of global demand, the successful development of the vaccine will also face a series of issues such as increasing production scale, ensuring transportation, ensuring equity, which require steam and in-depth cooperation of the international community.

Since the outbreak of the New Crown outbreak, many scientific research institutions around the world have invested in vaccine research and development. Data updated by WHO on July 20th show that at least 24 neo-coronavirus vaccines are currently in clinical studies worldwide, with 142 candidates in preclinical research.

The world is built on earth, and the common destiny is in the hands of countless people.